Zions Bancorporation National Association UT Sells 30,370 Shares of Novo Nordisk A/S $NVO

Zions Bancorporation National Association UT lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 45.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,059 shares of the company’s stock after selling 30,370 shares during the period. Zions Bancorporation National Association UT’s holdings in Novo Nordisk A/S were worth $2,001,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares in the last quarter. AQR Capital Management LLC raised its stake in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares in the last quarter. Stratos Wealth Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 26.9% during the 2nd quarter. Stratos Wealth Advisors LLC now owns 3,928 shares of the company’s stock valued at $271,000 after purchasing an additional 832 shares during the last quarter. Finally, Chevy Chase Trust Holdings LLC increased its position in Novo Nordisk A/S by 8.4% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 3,696 shares of the company’s stock worth $255,000 after purchasing an additional 287 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. Morgan Stanley restated an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Seven equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Stock Up 1.4%

Shares of NYSE NVO opened at $49.59 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The firm has a market cap of $221.43 billion, a PE ratio of 14.29 and a beta of 0.67. The company’s fifty day simple moving average is $53.80 and its 200 day simple moving average is $53.26. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.